Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
| ▸ | USP2 | O75604 | 1/20 | 0.30 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13575309 | 1.00 | SMN1; SMN2 (0.32) | SMN1; SMN2HSD17B10L3MBTL1USP2TSHR | |
| SCHEMBL13575316 | 1.00 | SMN1; SMN2 (0.32) | SMN1; SMN2HSD17B10L3MBTL1USP2TSHR | |
| SCHEMBL21166397 | 0.84 | L3MBTL1 (0.31) | L3MBTL1USP2TSHR | |
| SCHEMBL25563107 | 0.83 | SMN1; SMN2 (0.34) | SMN1; SMN2HSD17B10USP2TSHR | |
| SCHEMBL18431517 | 0.82 | CA1 (0.33) | — | |
| SCHEMBL18867108 | 0.82 | CA1 (0.33) | — | |
| SCHEMBL9004535 | 0.81 | MMP1 (0.35) | L3MBTL1 | |
| SCHEMBL9004534 | 0.81 | MMP1 (0.35) | L3MBTL1 | |
| SCHEMBL9004533 | 0.81 | MMP1 (0.35) | L3MBTL1 | |
| SCHEMBL22420077 | 0.79 | EPHX1 (0.37) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130072469-A1 | HETEROARYL COMPOUNDS AND USES THEREOF | CELGENE AVILOMICS RESEARCH, INC. (US) | 2013-03-21 | — | — | US | disclosed |
| US-20110230476-A1 | PI3 KINASE INHIBITORS AND USES THEREOF | AVILA THERAPEUTICS, INC. (US) | 2011-09-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110230476-A1 | PI3 KINASE INHIBITORS AND USES THEREOF | PIK3CA, PIK3CB, PIK3C2B | SMN1; SMN2 3609/4885HSD17B10 2153/4885L3MBTL1 1825/4885 |
| US-20130072469-A1 | HETEROARYL COMPOUNDS AND USES THEREOF | ABCG2, CYP3A43, CYP3A5 | SMN1; SMN2 2352/4885HSD17B10 223/4885L3MBTL1 3899/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.